Navigation Links
Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
Date:9/26/2013

GREENWOOD VILLAGE, Colo., Sept. 26, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a financing transaction that will provide $25 million in gross proceeds to the Company.  The financing is a registered direct placement of common stock of the Company.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

The Company has entered into a definitive agreement with a limited number of purchasers, mainly institutional investors, in connection with the registered direct placement of common stock of the Company, in which the investors have agreed to purchase an aggregate of 4,600,319 shares of common stock of the Company pursuant to the Company's effective registration statement at an offering price of $5.50 per share, for a total of $25 million of gross proceeds.  The Company is not using any placement agent for this offering. A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

The closing of the registered direct placement of the common stock of the Company is expected to take place on or about September 30, 2013, subject to satisfaction of customary closing conditions.  The net proceeds from this offering will be used for general corporate purposes, including continuation and completion of our Ampion and Optina clinical trials, potential submission of a BLA relating to Ampion and a NDA relating to Optina, executing a long term supply agreement of the Human Serum Albumin source material for Ampion, acquisition and/or leasing of new manufacturing equipment and manufacturing facility for Ampion, and the potential hiring of additional personnel to manufacture Ampion.  

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com



'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Ampio Pharmaceuticals Schedules 2012 Update Webcast
4. Four-Time Triathlon World Champion Melanie McQuaid Selects Polar USA as Official Heart Rate Training Solution
5. Ampios CEO and CSO Send Message to Shareholders
6. Ampio Pharmaceuticals Announces Proposed Public Offering
7. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
8. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
9. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
10. Ampio Pharmaceuticals Announces Closing of Public Offering
11. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2019)... ... July 10, 2019 , ... ... clinical study from Ohio State University Wexner Medical Center for PrimaVie®, its ... acid, and micro minerals. Natreon is committed to continued scientific investment and ...
(Date:7/10/2019)... , ... July 10, 2019 , ... DidCBDWork.com ... world for the past 18 months, does CBD actually work? It seems like depending ... snake oil. , DidCBDWork.com instead aims to get testimonials of real CBD users, ...
(Date:7/9/2019)... ... July 10, 2019 , ... FDA Data Integrity, ... Cerulean Associates LLC and FDAnews**, Oct. 21-22, 2019, Doubletree by Hilton Hotel Bethesda ... Register by Sept. 23 and Save $200 , FDA gives simple instructions to ...
Breaking Medicine Technology:
(Date:7/10/2019)... ... July 10, 2019 , ... Foggiare --the first and only ... and effective beauty and wellness technology. Developed by Sauna Italia , an Italian ... already a proven success in over 180 locations in Europe and Asia. Slim-Up is ...
(Date:7/10/2019)... ... July 10, 2019 , ... Given that ... Grove Fertility (SGF) remains committed to its core mission of fertility education ... of July, the practice will host six in-person seminars and three virtual webinars ...
(Date:7/9/2019)... ... ... Excellence is excited to offer laser vaginal rejuvenation. Laser vaginal rejuvenation gives women a less ... painful sex , vaginal dryness and burning , vaginal ... vaginal pH imbalances , recurrent vaginal infections , vaginal ...
(Date:7/9/2019)... ... July 09, 2019 , ... Complete Nutrition , a ... transition from a brick-and-mortar only business toward an e-commerce company. With 15 years of ... meet the growing demands of digital consumers. , As part of the transition, ...
(Date:7/9/2019)... ... July 09, 2019 , ... Smile Brands Inc., ... to more than 400 affiliated offices across 17 states, is pleased to announce ... Brands will provide full-service administrative support to the practice, including; purchasing, payroll, accounting, ...
Breaking Medicine News(10 mins):